| |
Scientific innovation in ligand targeting has spurred the development of many different types of radiopharmaceuticals (RPs) with a wide range of clinical uses. As those uses have grown, developers of RP products are faced with a regulatory environment that can be a challenge to navigate. We have a roadmap – read our guide for the details. Learn more. Premier Research. Built for Biotech℠
|
|
Today’s Big NewsNov 9, 2023 |
| By Max Bayer Novavax is looking to shave off an additional $300 million in costs in addition to reductions announced six months ago. The company's R&D and SG&A spend on the year is expected to be roughly 30% lower than in 2022. |
|
|
|
By Nick Paul Taylor AstraZeneca is buying its way back into the obesity drug gold rush. Months after dropping its own oral GLP-1 agonist, the Big Pharma has agreed to pay Eccogene $185 million for a similar small molecule that it believes can stake a claim to a market targeted by Eli Lilly, Novo Nordisk, Pfizer and others. |
By James Waldron By far the most brutal cutbacks were at SQZ, which is letting go of fully 80% of its workforce as the cell therapy company seeks a long-term survival plan. |
Sponsored by Resilience US, Inc. Digital twins can help biomanufacturing organizations spot and avoid failures that lead to costly delays. Explore this article to find out how. |
By Gabrielle Masson Adaptimmune Therapeutics, Monte Rosa Therapeutics and Intellia Therapeutics are all throwing programs to the discard pile. |
Sponsored by IQVIA Greg Lever, Director within the IQVIA Applied Data Science Center, reveals how modeling technology is being used to unlock value and enhance the experience of trial participants. |
By Nick Paul Taylor This time, it’s conclusive. Sixteen months after saying it lacked the results to draw firm conclusions, Atara Biotherapeutics is back with data showing its multiple sclerosis cell therapy was hammered by placebo, prompting the biotech to outline plans to slash its spending on the program. |
By Helen Floersh Like many powerful things, amphotericin B is also very toxic. Now, researchers have developed a derivative of the famous fungicidal that prevents it from harming the kidneys, with implications for other antimicrobial drugs. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
By Zoey Becker While Bayer's P13K Aliqopa couldn't prove its worth in a confirmatory trial, Novo's Levemir faced manufacturing issues and troubles with patient coverage, leading the two to separately withdraw their products. |
By Joseph Keenan Sygnature Discovery, a U.K.-based preclinical contractor, is pumping 3.75 million pounds sterling ($4.6 million) into Azenta Life Sciences’ compound management storage system that will allow it to store customer libraries. |
By Andrea Park Acutus Medical is planning to cut a majority of its jobs as it narrows its focus to only the most potentially profitable pursuits. |
By Nick Paul Taylor Moderna wants you to “Spikevax that body.” In an ad that contrasts sharply with Pfizer’s celeb-loaded TV spot, the mRNA specialist is pitching its COVID-19 vaccine as another part of a healthy lifestyle in a bid to counter falling sales. |
Fierce podcastsDon’t miss an episode |
| | Hello Heart is a U.S.-based company with offices in California and New York, and it also has a significant presence in Israel, with the majority of its roughly 80 employees there working from the Tel Aviv office. In this week’s episode of “Podnosis,” Hello Heart CEO Maayan Cohen, who resides in Tel Aviv, shares her personal experience during a challenging moment when she was on her way to the annual HLTH conference in Las Vegas and heard about the October 7th attack by Hamas on Israel. |
|
|---|
|
|
| WebinarWatch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| |
|
